Eris Lifesciences jumps 10% as investors cheer JV with MJ Biopharm
The JV, dubbed Eris Biopharm, would be in the ratio of 70:30, with Eris holding a 70 per cent stake.
The JV, dubbed Eris Biopharm, would be in the ratio of 70:30, with Eris holding a 70 per cent stake.